PURPOSE:Recent data on selected patients suggest a reduction in the incidence of venous thromboembolism with the use of statins. The objective of this study is to evaluate the influence of statins use on the incidence of venous thromboembolism (VTE) in patients with solid organ tumor (SOT).
METHODS:We conducted a retrospective, case-control study, reviewing 740 consecutive patients admitted to Albert Einstein Medical Center (AEMC), Philadelphia with a diagnosis of breast, lung, colon, prostate, stomach, esophagus, pancreas, ovary, kidney or brain cancer, between October 2004 and September 2007. Patients who had been treated with anticoagulation therapy before the first visit at AEMC were excluded. The occurrence of VTE, risk factors for VTE, and use of statins were recorded. The patients who either used statins for less than 2 months or never used statins were allocated to the control group.
RESULTS:The mean age of the entire study population was 65 years (s.d. =13). 52% of the patients were women and 76% were African American. The overall incidence of VTE was 18% (N = 132); 31% of patients had a history of dyslipidemia; and 26% (N = 194) were on statins. Among patients on statins, 8% (N = 16) developed a VTE compared to 21% (N = 116) in the control group. [Odds ratio (OR) 0.33, 95% CI = 0.192–0.578, P value < 0.001]. A logistic regression analysis that included factors related to VTE (smoking, documented metastatic disease, current use of chemotherapy, immobilization, and use of aspirin) along with statins use yielded the same results.
CONCLUSION:In this study, the use of statins appears to be associated with a significant reduction in the occurrence of VTE, irrespective of smoking, documented metastatic disease, current use of chemotherapy, immobilization, and use of aspirin.
CLINICAL IMPLICATIONS:This possible protective effect of statins on the occurrence of VTE warrants further investigation.
DISCLOSURE:Danai Khemasuwan, No Financial Disclosure Information; No Product/Research Disclosure Information